TY - JOUR
T1 - International Society for Quality of Life Research commentary on the draft European Medicines Agency reflection paper on the use of patient-reported outcome (PRO) measures in oncology studies
AU - Kyte, Derek
AU - Reeve, Bryce B.
AU - Efficace, Fabio
AU - Haywood, Kirstie
AU - Mercieca-Bebber, Rebecca
AU - King, Madeleine T.
AU - Norquist, Josephine M.
AU - Lenderking, William R.
AU - Snyder, Claire
AU - Ring, Lena
AU - Velikova, Galina
AU - Calvert, Melanie
N1 - Publisher Copyright:
© 2015, Springer International Publishing Switzerland.
PY - 2016/2/1
Y1 - 2016/2/1
N2 - In 2014, the European Medicines Agency (EMA) released for comment a draft reflection paper on the use of patient-reported outcome (PRO) measures in oncology studies. A twelve-member International Society for Quality of Life Research (ISOQOL) taskforce was convened to coordinate the ISOQOL response. Twenty-one ISOQOL members provided detailed comments and suggestions on the paper: 81 % from academia and 19 % from industry. Taskforce members consolidated and further refined these comments and shared the recommendations with the wider ISOQOL membership. A final response was submitted to the EMA in November 2014. The impending publication of the EMA reflection paper presents a valuable opportunity for ISOQOL to comment on the current direction of EMA PRO guidance and strategy. The EMA paper, although focused on cancer, could serve as a model for using PROs in other conditions, as it provides a useful update surrounding some of the design issues common to all trial research including PRO endpoints. However, we believe there are a number of additional areas in need of greater consideration. The purpose of this commentary is therefore to highlight the strengths of this timely and potentially useful document, but also to outline areas that may warrant further discussion.
AB - In 2014, the European Medicines Agency (EMA) released for comment a draft reflection paper on the use of patient-reported outcome (PRO) measures in oncology studies. A twelve-member International Society for Quality of Life Research (ISOQOL) taskforce was convened to coordinate the ISOQOL response. Twenty-one ISOQOL members provided detailed comments and suggestions on the paper: 81 % from academia and 19 % from industry. Taskforce members consolidated and further refined these comments and shared the recommendations with the wider ISOQOL membership. A final response was submitted to the EMA in November 2014. The impending publication of the EMA reflection paper presents a valuable opportunity for ISOQOL to comment on the current direction of EMA PRO guidance and strategy. The EMA paper, although focused on cancer, could serve as a model for using PROs in other conditions, as it provides a useful update surrounding some of the design issues common to all trial research including PRO endpoints. However, we believe there are a number of additional areas in need of greater consideration. The purpose of this commentary is therefore to highlight the strengths of this timely and potentially useful document, but also to outline areas that may warrant further discussion.
KW - European Medicines Agency
KW - HRQL
KW - Health-related quality of life
KW - International Society for Quality of Life Research
KW - Oncology
KW - PROs
KW - Patient-reported outcomes
UR - http://www.scopus.com/inward/record.url?scp=84955372111&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84955372111&partnerID=8YFLogxK
U2 - 10.1007/s11136-015-1099-z
DO - 10.1007/s11136-015-1099-z
M3 - Article
C2 - 26275979
AN - SCOPUS:84955372111
SN - 0962-9343
VL - 25
SP - 359
EP - 362
JO - Quality of Life Research
JF - Quality of Life Research
IS - 2
ER -